Anti-BRD7; clone BRM 2D3

Code: MABE1529 D2-231

Application

This Anti-BRD7 Antibody, clone BRM 2D3 is validated for use in Western Blotting, Immunoprecipitation for the detection of BRD7.

Western Blotting Analysis: 1...


read more

Your Price
€414.00 EACH
€509.22 inc. VAT

Application

This Anti-BRD7 Antibody, clone BRM 2D3 is validated for use in Western Blotting, Immunoprecipitation for the detection of BRD7.

Western Blotting Analysis: 1.0 µg/mL from a representative lot detected BRD7 in 10 µg of HEK293 and HeLa cell lysates.
Immunoprecipitation Analysis: A representative lot immunoprecipitated BRD7 from H1299 cell lysate (Courtesy of Thomas Dobner, Institut fur Medizinische Mikrobiologie und Hygiene, Universitat Regensburg, D-93053 Regensburg, Germany).

Research CategoryEpigenetics & Nuclear Function

Research Sub CategoryChromatin Biology

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Bromodomain-containing protein 7 (UniProt Q9NPI1; also known as 75 kDa bromodomain protein, Protein CELTIX-1) is encoded by the BRD7 (also known as BP75, CELTIX1) gene (Gene ID 29117) in human. BRD7 is a ubiquitously expressed single bromodomain-/BRD-containing member of the family of BRD-containing proteins. BRD7 functions as a subunit of the SWI/SNF chromatin-remodeling complex involved in transcription regulation. It also interacts with the well known tumor suppressor p53 to trans-activate genes involved in cell cycle arrest. BRD7 is downregulated in colorectal carcinoma and nasopharyngeal carcinoma, and BRD7 overexpression is reported to inhibit nasopharyngeal carcinoma cell proliferation via cell cycle arrest by transcriptionally regulating ras/MEK/ERK, Rb/E2F, b-catenin and ERK pathways. BRD7 mRNA has been identified as a silencing target of miR-300, overexpression of miR-300 promotes the proliferation, invasion and EMT of osteosarcoma cells through targeting BRD7 mRNA.

Immunogen

Recombinant human BRD7.

Linkage

Replaces: MABE66

Other Notes

Concentration: Please refer to lot specific datasheet.

Physical form

Purified rat monoclonal IgG2aκ antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Protein G purified.

Format: Purified

Quality

Evaluated by Western Blotting in Jurkat cell lysate.

Western Blotting Analysis: 1.0 µg/mL of this antibody detected BRD7 in 10 µg of Jurkat cell lysate.

Specificity

Clone BRM 2D3 detects human 75 kDa bromodomain protein, also known as protein CELTIX-1.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Target description

~75 kDa observed. 74.14 kDa (isoform 1), 74.27 kDa (isoform 2) calculated. Added Uncharacterized band(s) may appear in some lysates.

antibody formpurified immunoglobulin
antibody product typeprimary antibodies
biological sourcerat
cloneBRM203, monoclonal
Gene Informationhuman ... BRD7(29117)
isotypeIgG2aκ
NCBI accession no.NP_001167455
Quality Level100
species reactivityhuman
technique(s)western blot: suitable, immunoprecipitation (IP): suitable
UniProt accession no.Q9NPI1
This product has met the following criteria to qualify for the following awards:



PROCEED TO CHECKOUT

HAVE AN ACCOUNT? LOGIN


GUEST CHECKOUT

Proceed as a guest. You will have the option to register to access exclusive pricing and stock availability features after checkout.